Cancer

Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Including Live Product Showcase Featuring the Company’s New Stratys™ System

Bionano will host a pre-conference scientific session that will include a live product demonstration of the Stratys™ system for high…

2 years ago

Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results

 ●Q4 and FY Revenue of $10.3 million and $40.2 million; a $8.4 million and 26% increase year-over-year ●Q4 and FY Income…

2 years ago

Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting

Moffitt’s preclinical findings strongly suggest PV-10 induces immunogenic cell death-associated immunogenicity in HPV-positive and HPV-negative HNSCC in vitro and in…

2 years ago

American Oncology Network Announces Leaders Participating in ACCC’s Annual Meeting & Cancer Center Business Summit

Alti Rahman and Susan Sabo-Wagner were selected as panelists at the Association of Cancer Care Centers event in Washington, D.C.…

2 years ago

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses…

2 years ago

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,…

2 years ago

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

• Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of…

2 years ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

–  Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first…

2 years ago

BioNTech Announces Planned Retirement of Sean Marett

Mainz, Germany, March 7, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Sean…

2 years ago

Oxford BioTherapeutics Announces Launch of Enhanced Discovery Platform, OGAP®-Verify, at World ADC Conference 2024

OGAP®-Verify allows for significantly enhanced sensitivity and specificity for improved target selection, dramatically accelerating drug target discoveryOGAP-Verify is now more…

2 years ago